Skip to content
Biodatica
Start free

Varian, a Siemens Healthineers Company

Burmingham, Alabama

OncologyantibodyPhase III
Compare Sign in to watch

What changed

Phase III trial registered: Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

6d agoTrial registeredJul 14, 2026Source filing (opens the source filing in a new tab)

Momentum

80no change

Momentum 80 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Nov 5, 2025

    Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018 · RECRUITING · sponsor: National Cancer Institute (NCI) · Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

    ClinicalTrials.gov · NCT07061977 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Oct 6, 2022

    Vaginal Stricture, Vaginal Stenosis · RECRUITING · sponsor: University of California, San Diego · Quantifying Radiation Induced Vaginal Stenosis

    ClinicalTrials.gov · NCT05002751 (opens the source filing in a new tab)

  3. Trial

    NA registered

    May 3, 2022

    Cervical Cancer by FIGO Stage 2018 · RECRUITING · sponsor: Varian, a Siemens Healthineers Company · Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

    ClinicalTrials.gov · NCT05197881 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources